

Vision for the Future: Strengthening Communication Across the AD Drug Development Community

Samantha Budd Haeberlein, Biogen, Vice-President and Head of Alzheimer's Disease), and Billy Dunn (FDA, Director, Division of Neurology Products)

CPAD, November 13, 2018

Some of the largest and deepest data sets are currently being generated by industry sponsors



Alois Alzheimer

“The first person to be cured of Alzheimer's is a person in a clinical trial”

AfricanAmericansAgainstAlzheimer's

Sharing of Data

- Opportunity / Benefit
- Barriers / Roadblocks/ Assumptions
- Engagement of CPAD

Barriers / Roadblocks/ Assumptions

Logistics

- Sharing of data during ongoing trials
- Placebo only?
- Timing of sharing in relation to Trial milestones / submission
- Format of data
- Informed Consent
- De-identification of data
- Additional Resources

Industry Management Questions

- Value of the data to the sponsor
- Cost of resources
- How will the data be used

Other Questions

- IP, rights to data
- Unintended consequences
- IT concerns / resources
- Contractual concerns / resources

Barriers / Roadblocks/ Assumptions

How will the data be used?

= Opportunity / Benefit



Levels of Commitment

